3TC

DRUG8 trials

Sponsors

Avexa, Boehringer Ingelheim, The HIV Netherlands Australia Thailand Research Collaboration, Michael Hoelscher, Gilead Sciences

Conditions

Acquired Immunodeficiency SyndromeAlzheimer Disease, Early OnsetHIVHIV InfectionsHIV-1 InfectionHIV-infection/Aids

Phase 1

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

CompletedNCT04552795

The University of Texas Health Science Center at San AntonioAlzheimer Disease, Early Onset

Start: 2021-02-15End: 2023-11-04Updated: 2024-08-09

Phase 2

AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV

CompletedNCT00126880

AvexaHIV Infections

Start: 2005-07-31End: 2008-01-31Updated: 2011-06-23

Abacavir and Lamivudine PK in Children

CompletedNCT01656122

The HIV Netherlands Australia Thailand Research CollaborationHIV

Start: 2012-07-31End: 2015-07-31Updated: 2016-02-22

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen

CompletedNCT01714414

Michael HoelscherHIV-1 Infection

Start: 2012-12-31End: 2017-02-28Updated: 2018-03-07

Phase 3

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

CompletedNCT00144183

Boehringer IngelheimAcquired Immunodeficiency Syndrome

Start: 2003-01-31End: 2007-01-31Target: 407Updated: 2013-11-04

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

CompletedNCT02616783

Gilead SciencesHIV-1 Infection

Start: 2015-12-22End: 2018-03-21Updated: 2020-03-04

Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients

Henan Genuine Biotech Co., Ltd.HIV-infection/Aids

Start: 2020-04-01End: 2022-08-01Target: 720Updated: 2020-03-11

Phase 4

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

CompletedNCT00144157

Boehringer IngelheimAcquired Immunodeficiency Syndrome

Start: 2003-06-30End: 2006-07-31Updated: 2013-11-14

Related Papers

Pharmacological targeting of tau‐induced retrotransposon activation

Alzheimer s & Dementia2025-12-01

A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)

npj Dementia2025-03-1210 citations

Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19

Frontiers in Medicine2023-03-1441 citations

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with <scp>HIV</scp>: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

HIV Medicine2022-05-0838 citations

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.

2021-03-0939 citations

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

2019-10-0136 citations